The startup develops a 3D bioprinting technology for creating a 3D Organ-on-a-chip, which replicates the microenvironment of human tissues for cell culture applications. This platform enables more accurate disease modeling and drug testing, improving the efficacy of treatments and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional cell culture methods often fail to accurately replicate the complex microenvironment of human tissues, leading to inaccurate disease models and unreliable drug testing results. This discrepancy between in vitro and in vivo conditions can result in ineffective treatments and poor patient outcomes.
Solution
EDmicBio develops a 3D bioprinting technology for creating 3D Organ-on-a-chip (OoC) models that mimic the in vivo microenvironment of human tissues. This platform enables the construction of more physiologically relevant cell cultures for disease modeling and drug discovery applications. By replicating the intricate cellular interactions and tissue architecture, the 3D OoC platform provides a more accurate and predictive model for assessing drug efficacy and toxicity, ultimately improving the development of effective treatments.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in drug discovery, disease modeling, and toxicology studies.
Features
- 3D bioprinting technology for precise construction of Organ-on-a-chip models
- Replicates the complex microenvironment of human tissues, including cellular interactions and tissue architecture
- Enables more accurate disease modeling and drug testing compared to traditional 2D cell cultures